GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyowa Kirin Co Ltd (TSE:4151) » Definitions » EV-to-EBIT

Kyowa Kirin Co (TSE:4151) EV-to-EBIT : 14.53 (As of May. 17, 2024)


View and export this data going back to 1949. Start your Free Trial

What is Kyowa Kirin Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Kyowa Kirin Co's Enterprise Value is 円1,043,704 Mil. Kyowa Kirin Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was 円71,809 Mil. Therefore, Kyowa Kirin Co's EV-to-EBIT for today is 14.53.

The historical rank and industry rank for Kyowa Kirin Co's EV-to-EBIT or its related term are showing as below:

TSE:4151' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.79   Med: 20.58   Max: 41.51
Current: 14.52

During the past 13 years, the highest EV-to-EBIT of Kyowa Kirin Co was 41.51. The lowest was 9.79. And the median was 20.58.

TSE:4151's EV-to-EBIT is ranked better than
61.38% of 668 companies
in the Drug Manufacturers industry
Industry Median: 17.9 vs TSE:4151: 14.52

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Kyowa Kirin Co's Enterprise Value for the quarter that ended in Sep. 2023 was 円1,016,823 Mil. Kyowa Kirin Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was 円71,809 Mil. Kyowa Kirin Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 7.06%.


Kyowa Kirin Co EV-to-EBIT Historical Data

The historical data trend for Kyowa Kirin Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyowa Kirin Co EV-to-EBIT Chart

Kyowa Kirin Co Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.42 29.70 23.29 22.04 18.69

Kyowa Kirin Co Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.76 18.69 19.39 20.79 14.16

Competitive Comparison of Kyowa Kirin Co's EV-to-EBIT

For the Drug Manufacturers - General subindustry, Kyowa Kirin Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyowa Kirin Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Kyowa Kirin Co's EV-to-EBIT falls into.



Kyowa Kirin Co EV-to-EBIT Calculation

Kyowa Kirin Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1043703.675/71809
=14.53

Kyowa Kirin Co's current Enterprise Value is 円1,043,704 Mil.
Kyowa Kirin Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円71,809 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kyowa Kirin Co  (TSE:4151) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Kyowa Kirin Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 ) =EBIT / Enterprise Value (Q: Sep. 2023 )
=71809/1016823.44
=7.06 %

Kyowa Kirin Co's Enterprise Value for the quarter that ended in Sep. 2023 was 円1,016,823 Mil.
Kyowa Kirin Co's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円71,809 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kyowa Kirin Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Kyowa Kirin Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyowa Kirin Co (TSE:4151) Business Description

Traded in Other Exchanges
Address
1-9-2,Otemachi, Chiyoda-ku, Otemachi Financial City Grand Cube, Tokyo, JPN, 100-0004
Kyowa Kirin Co Ltd is a drug manufacturing company that focuses on biologic medicines. Its operations emphasize four categories: nephrology, oncology, immunology and allergy, and the central nervous system. The company has two reportable segments, Pharmaceuticals and Biochemicals. The pharmaceuticals business manufactures and sells ethical pharmaceuticals, diagnostic reagents, and other products. The biochemicals business manufactures and sells raw materials for pharmaceutical and industrial use, mainly amino acids, nucleic acids and related compounds, healthcare products, and others.

Kyowa Kirin Co (TSE:4151) Headlines

No Headlines